eBulletin Newsletter
NCCN Flash Updates: NCCN Guidelines Updated for B-Cell Lymphomas
NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for B-Cell Lymphomas. These NCCN Guidelines® are currently available as Version 4.2023.
Link directly to the Updates section of the NCCN Guidelines: B-Cell Lymphomas
Diffuse Large B-Cell Lymphoma
BCEL-C 3 of 6
- Third-line and subsequent therapy
- Added: Bispecific T-cell engager therapy - Epcoritamab-bysp (including patients with disease progression after transplant or CAR T-cell therapy) as a category 2A recommendation with corresponding footnote: Epocritamab-bysp is FDA approved for relapsed or refractory DLBCL, HGBL with translocations of MYC and BCL2 and/or BCL6 (double-/triple-hit lymphoma), and HGBL, NOS, as well as DLBCL arising from FL and MZL. See Epcoritamab-bysp prescribing information for the management of cytokine release syndrome (CRS) and other toxicities.
Histologic Transformation of Indolent Lymphomas to DLBCL
HTBCEL-A 1 of 2
- Systemic Therapy Regimens (no intention to proceed to transplant)
- Added: Bispecific T-cell engager therapy - Epcoritamab-bysp (only after at least two lines of systemic therapy; including patients with disease progression after transplant or CAR T-cell therapy) as a category 2A, preferred recommendation with corresponding footnote: Epocritamab-bysp is FDA approved for relapsed or refractory DLBCL, HGBL with translocations of MYC and BCL2 and/or BCL6 (double-/triple-hit lymphoma), and HGBL, NOS, as well as DLBCL arising from FL and MZL. See Epcoritamab-bysp prescribing information for the management of cytokine release syndrome (CRS) and other toxicities.
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.
Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.
About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content.
Subscribe to NCCN Flash Updates™
Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: https://private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works.
Access information on permissions and licensing of NCCN Content
Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.